

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)
In Non-small cell lung cancer Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Erlostar Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated. In Pancreatic cancer Pancreas are very essential for digestion of whatever you eat and also for metabolism of blood sugar levels as they produce the body?s natural insulin. This medicine will help to control pancreatic cancer, and will relieve the symptoms such as, lack of appetite or unexplained weight loss. Erlostar Tablet helps to stop the action of those chemicals that aid in pancreatic cancer growth and spread. It will help you live a longer and healthier life.
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Erlostar Tablet is to be taken empty stomach.
Erlostar Tablet is an anti-cancer medication. Epidermal growth factor receptors (EGFR) are expressed on the lung cancer cell surfaces that modulate their growth. This medicine works by binding the chemical messenger, EGFR, hence, inhibits the cancer signaling pathways mediated by EGFR. This is how it restricts further growth of the cancer cells.
Consult your Doctor: Please consult your doctor regarding the safety of consuming alcohol with Erlostar Tablet . Experts have not found evidence of alcohol impairing the effectiveness of the medicine.
Seek medical advice from your doctor: Erlostar Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Doctor consultation is advised.
Seek medical advice from your doctor: Erlostar Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Seek medical advice from your doctor: It is not known whether Erlostar Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Safe when prescribed by an expert: Erlostar Tablet is safe to use in patients with kidney disease. No dose adjustment of Erlostar Tablet is recommended. Use of this medicine is not advised in patients with severe kidney disease.
Caution Advised: Erlostar Tablet should be used with caution in patients with liver disease. Dose adjustment of Erlostar Tablet may be needed. Doctor consultation is advised. Limited information is available on the use of Erlostar Tablet in these patients. No dose adjustment is recommended in patients with mild to moderate liver disease.
If you forget a dose of Erlostar Tablet , simply continue with your regular schedule and do not take a double dose.
Lupin Ltd, 3rd floor Kalpataru Inspire, Off. W E Highway, Santacruz (East), Mumbai 400 055. India
Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilmans: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1735-36
Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 954-55
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 489-90
Erlotinib. Seymour, Indiana: Schwarz Pharma Manufacturing; 2014 (23 Jan. 2019)
Drugs and Lactation Database (LactMed) (18 Feb. 2020)
Central Drugs Standard Control Organisation (CDSCO) (27 Mar. 2019)
Erlotinib (25 Jul. 2024)
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.